The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The potential use of multi-gene molecular MRD testing in AML
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, briefly discusses the potential use of multi-gene molecular measurable residual disease (MRD) testing for the prognosis of patients with acute myeloid leukemia (AML), emphasizing the importance of using highly sensitive approaches. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
